Document Detail

Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload.
MedLine Citation:
PMID:  3734266     Owner:  NLM     Status:  MEDLINE    
A patient who developed severe iron overload cardiomyopathy is described. Venesection could not be performed because the patient had chronic anemia. Deferoxamine mesylate, a chelating agent, was administered daily for more than 2 years and produced significant improvement in ventricular function which was associated with a biopsy-proven decrease in myocardial iron stores. This is the first reported case in which a severe cardiomyopathy due to iron overload was reversed by chelation therapy alone.
P S Rahko; R Salerni; B F Uretsky
Related Documents :
20392616 - Serum ferritin levels are associated with vascular damage in patients with nonalcoholic...
19549696 - Neutrophil gelatinase-associated lipocalin (ngal) reflects iron status in haemodialysis...
9654156 - Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and tr...
18256566 - Etiology and management of anemia in patients with heart failure: how much iron is miss...
16948806 - Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-bl...
7704956 - Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a ma...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  8     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1986 Aug 
Date Detail:
Created Date:  1986-09-17     Completed Date:  1986-09-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  436-40     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Macrocytic / complications*
Anemia, Megaloblastic / complications*
Deferoxamine / therapeutic use*
Diabetes Complications
Heart Failure / drug therapy*,  etiology,  pathology
Iron / toxicity*
Grant Support
Reg. No./Substance:
70-51-9/Deferoxamine; 7439-89-6/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recainam, a potent new antiarrhythmic agent: effects on complex ventricular arrhythmias.
Next Document:  Ectopic atrial tachycardia after transvenous catheter ablation of a posteroseptal accessory pathway.